Author Archives: Margarida Maia PhD

Rozanolixizumab May Safely Ease Symptom Severity in gMG Patients

Rozanolixizumab, UCB’s investigational antibody, may ease symptom severity in adults with generalized myasthenia gravis (MG), and help them carry on with daily activities, top-line data from the Phase 3 MycarinG study suggests. Moreover, rozanolixizumab, given as an under-the-skin (subcutaneous) infusion, was found to be generally safe and…

Soliris May Be Safe, Effective for Rituximab-refractory gMG

Soliris (eculizumab) appears to be safe and effective for patients with hard-to-treat generalized myasthenia gravis (gMG) who have acetylcholine receptor (AChR) antibodies, a study has found. Its benefits were extended to a particular group of patients from the Phase 3 REGAIN clinical trial and its extension study who were treated…

Myasthenic Crisis During Sedation Leads to Diagnosis

A recent case report describes an elderly woman who was first diagnosed with myasthenia gravis (MG) after experiencing a myasthenic crisis while being sedated for a surgical procedure. “This case reports a form of discovery of [a] myasthenic crisis outside the usual circumstance,” its authors wrote. “The prognosis depends…

Exercise Program Improved Muscle, Physical Function

Muscle and physical function improved in patients with clinically stable myasthenia gravis (MG) who participated in an individually tailored six-month exercise program, a small study has found. The exercise program, which combined aerobic and resistance training with stretches, was well-tolerated by all participants. “Physical exercise is safe, effective, and…

Case Study: COVID-19 May Trigger MG, But Outcomes Can Be Good

An elderly man in India developed generalized myasthenia gravis (MG) after contracting COVID-19, but his condition improved after he was given adequate treatment, a case report described. This new case adds weight to eight other recent reports indicating that COVID-19 may trigger new-onset MG, with most cases occurring in…

Thymectomy May Be Better for Early-onset MG

Thymectomy – surgical removal of the thymus gland — may be a better option for treating patients with early-onset non-thymomatous myasthenia gravis (MG), a study has found. According to study data, the surgical procedure did not confer an added benefit over non-invasive treatment options for patients with late-onset disease.

Micro RNA Molecule miR-146a May Be Useful Diagnostic Marker

A micro RNA molecule called miR-146a was found at high levels in the blood of patients with myasthenia gravis (MG), and this is thought to contribute to disease development, a single-site study suggests. The findings put forward miR-146a as “a suitable candidate marker for diagnosing MG,” the researchers wrote.

2021 Myasthenia Gravis Survey Results

BioNews Survey Infographic

Myasthenia Gravis News conducted a survey from Feb. 11-March 28 to gain greater insight into the characteristics of the MG community and disease management. Results of the survey have now been published. Click on the image to view the infographic, and click here to read the story.